Pilot study of GFT505 on insulin sensitivity and hepatic glucose production in insulin-resistant patients with abdominal obesity

Phase 2, randomised, double-blind trial of elafibranor in insulin resistance (IR), Abdominal adiposity (ABCD) and prediabetes (2 arms), sponsored by Genfit. Primary endpoints: Change in glucose infusion rate (GIR) after 8 weeks of treatment and Change in hepatic glucose production (HGP) after 8 weeks of treatment. Started Nov 2010; status: completed.